## PFE: Pfizer Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.9% below STRENGTH zone (3.0-6.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Pfizer Inc. $PFE Shares Bought by Generali Investments CEE investicni spolecnost a.s.**
- Source: MarketBeat | 20251222T110850 | Neutral | Relevance: 100%
- Generali Investments CEE investicni spolecnost a.s. significantly increased its stake in Pfizer Inc. (NYSE:PFE) by 76.4% in the third quarter, acquiring an additional 47,319 shares, bringing their total holdings to 109,269 shares valued at approximately $2.784 million. This comes as Pfizer declared a quarterly dividend of $0.43, implying a 6.8% yield, amidst mixed analyst sentiment following the company's FY2025 guidance of 3.000â€“3.150 EPS, resulting in an average "Hold" rating and a target price of $28.06 from analysts. The article also highlights other large institutional investors modifying their Pfizer holdings and various ongoing developments, including Pfizer's push into weight-loss drugs and new liver cancer trials.

**2. First Bank & Trust Buys 80,401 Shares of Pfizer Inc. $PFE**
- Source: MarketBeat | 20251221T120931 | Neutral | Relevance: 100%
- First Bank & Trust significantly increased its stake in Pfizer Inc. (NYSE:PFE) by 112.9% in the third quarter, now owning 151,617 shares valued at $3.863 million. This strategic move comes amidst a muted 2026 outlook and trimmed profit guidance for Pfizer, leading to analyst downgrades and a "Hold" consensus rating with an average price target of $28.06. Despite near-term headwinds, Pfizer offers a 6.8% dividend yield and is pursuing potential growth catalysts through licensing a weight-loss drug and advancing a liver cancer trial.

**3. Wedge Capital Management L L P NC Has $26.91 Million Stock Position in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251221T120838 | Neutral | Relevance: 100%
- Wedge Capital Management L L P NC significantly reduced its stake in Pfizer Inc. by 17.6% in the third quarter, now holding 1,056,239 shares valued at $26.91 million. Despite a muted 2026 outlook and trimmed profit guidance leading to analyst downgrades, Pfizer is making strategic moves in weight-loss drugs and oncology, and offers an attractive dividend yield. Institutional investors collectively own 68.36% of Pfizer's stock.

**4. Voya Investment Management LLC Acquires 688,225 Shares of Pfizer Inc. $PFE**
- Source: MarketBeat | 20251220T140832 | Neutral | Relevance: 100%
- Voya Investment Management LLC substantially increased its stake in Pfizer Inc. by 15% during the third quarter, acquiring 688,225 additional shares, bringing their total holdings to 5,281,953 shares valued at approximately $134.6 million. Despite a "Hold" consensus rating from analysts and recent downgrades, Pfizer offers a high dividend yield of about 6.8% and is making strategic moves into weight-loss drugs and oncology, which could drive future upside. The company's future performance hinges on successful pipeline execution and commercial recovery, particularly as it navigates declining COVID product sales and patent expirations.

**5. Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)**
- Source: ts2.tech | 20251220T130828 | Somewhat-Bearish | Relevance: 100%
- Pfizer Inc. (NYSE: PFE) is navigating a "transition" period, with its 2026 guidance indicating lower COVID product revenue and patent expirations. Investors are weighing the impact of TrumpRx drug-pricing deals, the company's significant dividend yield, and its strategic pipeline investments in obesity and immunology to drive future growth. While analysts are cautiously optimistic, the market is awaiting concrete evidence of post-COVID and post-loss-of-exclusivity growth, with Pfizer's next major update being its Q4 and full-year 2025 performance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $27 | $28 | -4% |
| 2025-12-15 | B of A Securiti | $28 | $29 | -3% |
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.3% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment negative (3 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $143.3B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.4 |
| Current P/E | 8.1 |
| YoY Growth | -3.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.4% to -1.9% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 48. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.91% (CS: 20) | Neutral |
| RSI_14 | 47.8 | Neutral |
| MACD Histogram | -0.09 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 1.005x | Above |
| vs SMA200 | 1.029x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.21
- **Stop Loss:** $24.05 (4.6% risk)
- **Target:** $26.37 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1034
- **Position Value:** $26,067.14
- **Portfolio %:** 26.07%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*